PDF Document

Source URL: shionogi616.tew-staging.com

• Food and Drug Administration
• Science
• Shionogi
• Health
• Medical statistics
• Off-label use
• Clinical trial
• Pharmacology
• Lymphoma
• Pharmaceutical sciences

Shionogi & Co., Ltd. Impact of the 2011 off the Pacific coast of Tohoku Earthquake Osaka, Japan, March 15, Shionogi would like to express condolences to the victims and sincerely hope for the recovery of the peop

Source URL: shionogi616.tew-staging.com

• Actuarial science
• Emergency management
• Risk
• Shionogi
• Disaster
• Tōhoku earthquake and tsunami
• Earthquake
• Forward-looking statement
• Business
• Management
• Ethics
• Risk management

PDF Document

Source URL: shionogi616.tew-staging.com

• Aalborg University
• Aarhus University
• University of Copenhagen
• Denmark
• Copenhagen
• College and university rankings
• Aalborg
• Shionogi
• QS World University Rankings
• Geography of Europe
• Europe
• Municipalities of Denmark

Shionogi Announces the Conducting of International Industry-Academic Collaboration, SHIONOGI Science Program, and Drug Discovery Competition, FINDS2011 Osaka, October 3, 2011 – Shionogi & Co., Ltd. (Head Office: Osaka;

Source URL: shionogi616.tew-staging.com

• Science
• Research
• Research and development
• Clinical trial
• Pharmaceutical sciences
• Shionogi
• Pharmacology
• Nursing research

Shionogi Enters into Exclusive Licensing Agreement with OncoTherapy Science to Develop and Market Cancer Peptide Vaccines Osaka, Japan, March 30, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Tes

Source URL: shionogi616.tew-staging.com

• Shionogi
• Immunology
• Vaccine
• Oncoantigen
• Peptide
• Cancer
• Medicine
• Health
• Vaccination

Shionogi participates in the Global Health Innovative Technology Fund Osaka, Japan, April 8, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announ

Source URL: shionogi616.tew-staging.com

• Medicine
• Health
• Tropical diseases
• Shionogi
• Neglected diseases

Shionogi and Shire to Collaborate on the Development and Commercialization of the Therapeutic Agents for Attention-Deficit/Hyperactivity Disorder Osaka, Japan, November 18, Shionogi & Co., Ltd. (Head Office: Osaka

Source URL: shionogi616.tew-staging.com

Financial Results for the Third Quarter of Fiscal Year 2012(Consolidated) February 4, 2013 Name of Listed Company: SHIONOGI & CO., LTD.

Source URL: shionogi616.tew-staging.com

• Financial statements
• Generally Accepted Accounting Principles
• Financial accounting
• Financial markets
• Balance sheet
• Net asset value
• Income tax in the United States
• Account
• Accumulated other comprehensive income
• Finance
• Accountancy
• Business

NOT FOR IMMEDIATE RELEASE SHIONOGI & CO., LTD ANNOUNCES THAT NALDEMEDINE MEETS PRIMARY ENDPOINT IN A PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION FLORHAM PARK, NJ (March 30, 2015) – Naldemedine, an i

Source URL: shionogi616.tew-staging.com

• Alcohols
• Phenols
• Pain
• Morphinans
• Ketones
• Opioid
• Cancer pain
• Methylnaltrexone
• Chemistry
• Organic chemistry
• Medicine

Shionogi Enters into Settlement Agreement with Generic Manufacturers over Crestor® Patent Osaka, Japan, March 26, Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter

Source URL: shionogi616.tew-staging.com

• Pyrimidines
• Rosuvastatin
• Statins
• Shionogi
• Organic chemistry
• Business
• Pharmaceutical drug
• Patent infringement
• Declaratory judgment
• Chemistry
• AstraZeneca
• Diols